Vanguard Group
CLPT icon

Vanguard Group’s ClearPoint Neuro CLPT Stock Holding History

Vanguard Group’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$24.2M Buy
1,766,677
+269,040
+18% +$4.99M ﹤0.01% 2535
2025
Q3 		$32.6M Buy
1,497,637
+22,517
+2% +$265K ﹤0.01% 2377
2025
Q2 		$17.6M Buy
1,475,120
+191,142
+15% +$2.41M ﹤0.01% 2612
2025
Q1 		$15.3M Buy
1,283,978
+35,585
+3% +$553K ﹤0.01% 2626
2024
Q4 		$19.2M Buy
1,248,393
+5,400
+0.4% +$69.9K ﹤0.01% 2605
2024
Q3 		$13.9M Buy
1,242,993
+26,627
+2% +$255K ﹤0.01% 2788
2024
Q2 		$6.56M Sell
1,216,366
-91,333
-7% -$529K ﹤0.01% 3127
2024
Q1 		$8.89M Sell
1,307,699
-995
-0.1% -$6.95K ﹤0.01% 3026
2023
Q4 		$8.89M Buy
1,308,694
+33,414
+3% +$189K ﹤0.01% 3015
2023
Q3 		$6.39M Buy
1,275,280
+55,784
+5% +$332K ﹤0.01% 3145
2023
Q2 		$8.83M Buy
1,219,496
+125,667
+11% +$1.07M ﹤0.01% 3017
2023
Q1 		$9.23M Buy
1,093,829
+72,487
+7% +$635K ﹤0.01% 2979
2022
Q4 		$8.65M Buy
1,021,342
+33,474
+3% +$317K ﹤0.01% 3018
2022
Q3 		$10.2M Buy
987,868
+7,806
+0.8% +$103K ﹤0.01% 2943
2022
Q2 		$12.8M Sell
980,062
-100,594
-9% -$1.03M ﹤0.01% 2852
2022
Q1 		$11.2M Buy
1,080,656
+154,867
+17% +$1.41M ﹤0.01% 3086
2021
Q4 		$10.4M Buy
925,789
+64,316
+7% +$963K ﹤0.01% 3179
2021
Q3 		$15.3M Buy
861,473
+38,439
+5% +$721K ﹤0.01% 3001
2021
Q2 		$15.7M Buy
823,034
+166,851
+25% +$3.22M ﹤0.01% 2963
2021
Q1 		$13.9M Buy
656,183
+61,107
+10% +$1.31M ﹤0.01% 2976
2020
Q4 		$9.46M Buy
595,076
+139,918
+31% +$1.26M ﹤0.01% 3024
2020
Q3 		$2.48M Hold
455,158
– – ﹤0.01% 3427
2020
Q2 		$1.62M Hold
455,158
– – ﹤0.01% 3492
2020
Q1 		$1.63M Buy
455,158
+123,141
+37% +$605K ﹤0.01% 3353
2019
Q4 		$1.59M Buy
332,017
+87,674
+36% +$363K ﹤0.01% 3511
2019
Q3 		$1.24M Buy
+244,343
New +$1M ﹤0.01% 3590

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
FCM
FirstWave Capital Management Miami, Florida $94.1M AUM
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group's CLPT Position: Q4 2025 in Review

Vanguard Group increased its ClearPoint Neuro (CLPT) stake by 18% in Q4 2025, buying an estimated $4.99M and bringing the position to 1,766,677 shares worth $24.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Vanguard Group first reported a position in CLPT in Q3 2019 and has held it in 26 quarters since. The position peaked at $32.6M in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q4 2025.

  • Vanguard Group held 1,766,677 shares of ClearPoint Neuro worth $24.2M as of Q4 2025.
  • Vanguard Group bought 269,040 ClearPoint Neuro shares in Q4 2025, an estimated $4.99M.
  • ClearPoint Neuro made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2535 holding.
  • Vanguard Group first reported a position in ClearPoint Neuro in Q3 2019 and has held it in 26 quarters since.
  • Vanguard Group's ClearPoint Neuro position peaked at $32.6M in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.